Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 9, 2026, 11:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 17,984 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adults Clear all
Completed Not applicable Interventional

Trial of the Impact of the Electronic Frailty Integrated With Social Needs

NCT05293730
View directory record Official record
Conditions
Aging
Interventions
eFRIEND, Usual Care
Behavioral · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years and older
Enrollment
2,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Jun 9, 2026, 11:49 PM EDT
Terminated Not applicable Interventional Results available

Assessment of the Precision of the Sherlock 3CG Tip Positioning System

NCT01275430
View directory record Official record
Conditions
No Specific Conditions Under Study. Primary Focus: Adult Subjects Who Require PICC Placement
Interventions
Sherlock 3CG, Blind Placement
Device · Other
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Jun 9, 2026, 11:49 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults

NCT07597928
View directory record Official record
Conditions
Healthy Adults, Healthy
Interventions
PF-08049820, Rabeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 9, 2026, 11:49 PM EDT
Completed Phase 2 Interventional Results available

[18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer

NCT02695628
View directory record Official record
Conditions
Adult Liver Carcinoma, Liver Cirrhosis
Interventions
18F-Fluoromisonidazole, Arterial Embolization, Computed Tomography, Positron Emission Tomography
Drug · Procedure · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
19 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Jun 9, 2026, 11:49 PM EDT
Completed Phase 3 Interventional

Evaluation of Manufacturing Lot of StaphVAX

NCT00211900
View directory record Official record
Conditions
Staphylococcal Infections, Chronic Kidney Failure
Interventions
S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine
Biological
Lead sponsor
Nabi Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Madison, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 3, 2008 · Synced Jun 9, 2026, 11:49 PM EDT
Completed Phase 4 Interventional Results available

The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy

NCT00666536
View directory record Official record
Conditions
Hypertension
Interventions
valsartan and amlodipine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Jun 9, 2026, 11:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Quantifying the Attentive Behaviors of Older Adults During Over-the-counter Drug Selection

NCT02188134
View directory record Official record
Conditions
Older Adults (65 Years and Older)
Interventions
Not listed
Lead sponsor
Michigan State University
Other
Eligibility
65 Years and older
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Jun 9, 2026, 11:49 PM EDT
Completed Not applicable Interventional

Grocery Prescription Program for Medicaid Adults With Hypertension or Type 2 Diabetes

NCT06033664
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hypertension
Interventions
Fresh Funds
Behavioral
Lead sponsor
Alison Gustafson
Other
Eligibility
18 Years to 64 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Jun 9, 2026, 11:49 PM EDT
Completed Phase 3 Interventional Results available

Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007

NCT03853798
View directory record Official record
Conditions
Pyruvate Kinase Deficiency
Interventions
Mitapivat
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
12
States / cities
Phoenix, Arizona • Oakland, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Jun 9, 2026, 11:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Vertical Transmission of Hepatitis C in Adult Children of Female Baby Boomers

NCT03038763
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic
Interventions
Eligibility Screening, HCV test
Other · Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 72 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Jun 9, 2026, 11:49 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer

NCT05125016
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
REGN4336, REGN5678
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
13
States / cities
Palo Alto, California • New Haven, Connecticut • Louisville, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 9, 2026, 11:49 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

A Urine Sample Collection Study in Apparently Healthy Adults and Adults With Chronic, Stable Morbidities

NCT05853016
View directory record Official record
Conditions
Healthy, Chronic Disease
Interventions
Urine collection for NEPHROCLEAR CCL14 Test
Diagnostic Test
Lead sponsor
Astute Medical, Inc.
Industry
Eligibility
21 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Gresham, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Jun 9, 2026, 11:49 PM EDT
Completed Not applicable Interventional Results available

Lifestyle Physical Activity to Reduce Pain and Fatigue in Adults With Fibromyalgia

NCT00383084
View directory record Official record
Conditions
Fibromyalgia
Interventions
Lifestyle physical activity (LPA), Fibromyalgia education
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Jun 9, 2026, 11:49 PM EDT
Completed Phase 2 Interventional

Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease

NCT00003849
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab
Biological
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
20
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Jun 9, 2026, 11:49 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)

NCT06077149
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSV vaccine
Biological
Lead sponsor
University of Rochester
Other
Eligibility
60 Years and older
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Jun 9, 2026, 11:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent

NCT01579149
View directory record Official record
Conditions
Healthy Volunteer
Interventions
plerixafor, Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
20 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Jun 9, 2026, 11:49 PM EDT
Completed Phase 1 Interventional

First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

NCT05054348
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
IO-108, IO-108 + pembrolizumab combination therapy, IO-108 + cemiplimab combination therapy
Biological
Lead sponsor
Immune-Onc Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
24
States / cities
Tucson, Arizona • Beverly Hills, California • Lone Tree, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Jun 9, 2026, 11:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Two Different Lion's Mane Extracts (Lions Mane Fruiting Body & Lions Mane Fruiting Body With Mycellium) on Cognitive Performance, Subjective Affect, Serum Biomarkers, and Gut Microbiota in Healthy Adults

NCT07405957
View directory record Official record
Conditions
Healthy Adult Females, Healthy Adult Male
Interventions
Lion Mane (Hericium erinaceus) fruiting body extract - Nordic Origin, Lions Mane (Hericium erinaceus) Fruiting body and mycelium, Maltodextrin (Placebo)
Dietary Supplement · Other
Lead sponsor
Applied Food Sciences Inc.
Industry
Eligibility
40 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Canfield, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jun 9, 2026, 11:49 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE

NCT03312907
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab, Rituximab, Rituximab-placebo, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
28
States / cities
Birmingham, Alabama • La Mesa, California • San Leandro, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Jun 9, 2026, 11:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigating Fitness Interventions in the Elderly (INFINITE)

NCT01048736
View directory record Official record
Conditions
Obesity, Older Adults, Sedentary
Interventions
Exercise Only, Exercise + Diet
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jun 9, 2026, 11:49 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)

NCT01992536
View directory record Official record
Conditions
Meningococcal Disease
Interventions
MenABCWY+OMV, MenABCWY+¼OMV, Placebo
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
10 Years to 25 Years
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
8
States / cities
Birmingham, Alabama • Madera, California • Paramount, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Jun 9, 2026, 11:49 PM EDT
Terminated Phase 2 Interventional

Radiation Therapy and Fluorouracil Before Surgery in Treating Patients With Primary or Recurrent Bile Duct Cancer

NCT00030511
View directory record Official record
Conditions
Extrahepatic Bile Duct Cancer, Liver Cancer
Interventions
fluorouracil, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2012 · Synced Jun 9, 2026, 11:49 PM EDT
Not yet recruiting Not applicable Interventional

Enhancing PAP Adherence Among Spanish-speaking Hispanic Adults With OSA

NCT05618444
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Automated Management (AM)
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Fontana, California • Kansas City, Kansas • Danville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jun 9, 2026, 11:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants

NCT07015398
View directory record Official record
Conditions
Healthy Participants
Interventions
NAL ER, Pirfenidone, Nintedanib
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Jun 9, 2026, 11:49 PM EDT